Pipeline

Our precisely delivered investigational therapies – with their systemic immunotherapeutic effects and favorable tolerability profiles observed to date – have the potential to significantly improve survival while maintaining quality of life throughout all stages of disease.

CAN-2409 Mechanism of Action

CAN-3110 Mechanism of Action

We are evaluating our viral immunotherapies in a variety of solid tumors, including prostate, lung, brain and pancreatic cancer. For more information on our clinical studies, click here. Please visit our Platforms page to learn more about our viral immunotherapy approach.

PROGRAM

INDICATION

PRECLINICAL

PHASE I

PHASE II

PHASE III

BLA Readiness

Adenovirus Platform

CAN-2409
Pancreatic Cancer*

Borderline Resectable
Pancreatic Adenocarcinoma, Fast Track Designation (FDA)

Borderline Resectable Pancreatic Adenocarcinoma, Fast Track Designation (FDA)

Phase II

Advanced Non-Metastatic Pancreatic Adenocarcinoma - Phase 2

CAN-2409
Lung Cancer

NSCLC + PD-1/PD-(L)1,
Fast Track Designation (FDA)

NSCLC + PD-1/PD-(L)1, Fast Track Designation (FDA)

Phase II

NSCLC + PD-1/PD-L1 - Phase 2

CAN-2409
Prostate Cancer

Localized, Intermediate/High Risk, Fast Track Designation (FDA), Special Protocol Assessment (FDA)

Localized, Intermediate/High Risk, Fast Track Designation (FDA), Special Protocol Assessment (FDA)

BLA Readiness

Intermediate/High Risk, under SPA - BLA Readiness

HSV Platform

CAN-3110
Brain Cancer

Recurrent High-Grade
Glioma, Fast Track
Designation (FDA)

Recurrent High-Grade Glioma, Fast Track Designation (FDA)

Phase I

Recurrent GBM - Phase 1

enLIGHTEN™ Discovery Platform

Solid Tumors

Solid Tumors

Preclinical

Undisclosed - Preclinical

SPA – special protocol assessment

*Enrollment paused, subject to additional funding